BioCryst Pharma (BCRX) PT Raised to $21 at Piper Sandler, 'we continue to recommend shares'
Piper Sandler analyst Tyler Van Buren raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $21.00 (from $20.00) while ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)